Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hologic, Inc. filings document the company’s transition from a Nasdaq-listed public issuer to a private company after its completed acquisition by funds managed by Blackstone and TPG. The record includes Form 25 notice for removal of Hologic common stock from Nasdaq listing and Form 15 certification to terminate registration or suspend Exchange Act reporting duties for its common stock.
Related 8-K disclosures cover material events, merger-related agreements and shareholder voting matters, capital-structure disclosures, governance and compensation arrangements, operating results, and clinical or regulatory developments tied to Hologic’s women’s health medical-technology business.
Hologic, Inc. insider reports tax-related share withholding
A Hologic executive, identified as President, Diagnostic Solutions, reported a routine equity transaction involving company common stock. On 11/14/2025, 561 shares of Hologic common stock were disposed of at $74.15 per share under transaction code “F,” which indicates shares were withheld to cover tax obligations upon settlement of previously granted restricted stock units whose service-based vesting conditions had been met. After this transaction, the executive beneficially owns 41,318 shares of Hologic common stock in direct ownership. No derivative securities transactions were reported in this filing.
Hologic Inc. Chief Financial Officer Form 4 filing details insider share activity. On 11/14/2025, the CFO reported the disposition of 1,333 shares of Hologic common stock at $74.15 per share, labeled as shares withheld to cover tax obligations related to the settlement of previously granted restricted stock units whose service-based vesting conditions were satisfied.
After this tax withholding transaction, the CFO beneficially owns 150,735 shares in total. This figure includes 41,121 restricted stock units and performance stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Hologic, Inc. (HOLX) reported an insider equity transaction by its Chief Operating Officer on a Form 4. On 11/14/2025, the COO had 1,342 shares of common stock withheld at a price of $74.15 per share.
According to the explanation, these shares were withheld to cover tax obligations arising from the settlement of restricted stock units whose service-based vesting conditions had been met. After this tax withholding transaction, the officer directly beneficially owned 77,610 shares of Hologic common stock.
Hologic Inc. (HOLX) disclosed an insider equity transaction by its General Counsel on a Form 4. On 11/14/2025, 337 shares of Hologic common stock were disposed of at $74.15 per share under transaction code "F", meaning the shares were withheld to cover tax obligations related to the settlement of previously granted restricted stock units whose service-based vesting conditions had been met. After this tax withholding, the officer directly beneficially owns 28,237 shares of Hologic common stock.
Hologic, Inc. (HOLX) reported an insider tax-withholding transaction by its Principal Accounting Officer. On 11/14/2025, the officer had 187 shares of common stock withheld, coded as an "F" transaction, at a price of $74.15 per share. This type of transaction reflects shares withheld to cover tax obligations tied to the settlement of previously granted restricted stock units whose service-based vesting conditions had been met. After this event, the officer beneficially owned 17,884 shares of Hologic common stock directly.
Hologic, Inc. filed its Annual Report on Form 10-K and disclosed a definitive agreement to be acquired by funds managed by Blackstone and TPG. The buyers will acquire all outstanding Hologic shares for $76.00 per share in cash, plus a non-tradable contingent value right (CVR) of up to $3.00 per share in cash, for total potential consideration of $79.00 per share. The CVR payments depend on achieving specified global revenue metrics in the Breast Health business in fiscal 2026 and 2027, and the transaction is expected to close in the first half of calendar 2026, subject to stockholder approval and regulatory and other customary conditions.
Hologic describes four main segments—Diagnostics, Breast Health, GYN Surgical and Skeletal Health—focused on women’s health through early detection and treatment. As of March 29, 2025, the aggregate market value of common stock held by non-affiliates was $13,566,017,923, and as of November 13, 2025, there were 222,905,228 common shares outstanding.
Hologic (HOLX) Chairman, President and CEO Stephen P. MacMillan reported routine equity transactions. On 11/07/2025, 50,405 shares of common stock were withheld to cover taxes at $74.10 per share tied to RSU/PSU settlements. On 11/10/2025, he received an award of 169,582 restricted stock units that vest in three equal annual installments beginning on November 10, 2025. On 11/11/2025, an additional 6,679 shares were withheld for taxes at $74.60.
Following these transactions, he beneficially owned 1,430,711 shares directly (including 1,079,673 deferred RSUs/PSUs) and 1,146,829 shares indirectly through the MacMillan Family Trust.
Hologic (HOLX) reported insider activity by its Group President, International. On 11/07/2025 and 11/11/2025, the officer had shares withheld for taxes upon settlement of performance/restricted stock units, totaling 1,420 at $74.10 and 178 at $74.60. After these events and a grant, direct holdings were 134,235 shares.
On 11/10/2025, the officer received 16,823 restricted stock units, which vest in equal installments on each of the first three anniversaries of the grant date, November 10, 2025. These RSUs settle one-for-one in Hologic common stock.
Hologic (HOLX) CFO reported equity transactions. On 11/10/2025, she received 43,741 restricted stock units that vest in three equal installments starting November 10, 2025. On 11/07/2025 and 11/11/2025, 9,427 and 1,449 shares were withheld to cover taxes upon PSU/RSU settlement at $74.1 and $74.6, respectively. After these transactions, she beneficially owns 152,068 shares, which includes 41,121 deferred RSUs/PSUs.
Hologic (HOLX) reported insider activity by its Chief Operating Officer. On November 10, 2025, the officer was granted 47,106 restricted stock units that vest in equal installments on each of the first three anniversaries of the grant date. The filing also shows share withholdings to cover taxes: 3,927 shares on November 7, 2025 and 1,701 shares on November 11, 2025, both coded “F.” After the reported transactions, the officer directly owned 78,952 shares. The RSUs settle one-for-one in common stock.